- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03244241
Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study
Basal-bolus Insulin Therapy With Insulin Degludec and Insulin Aspart Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The aim of this study is to investigate and compare the efficacy and safety of basal-bolus insulin therapy using the insulin analogue, insulin degludec once daily and insulin aspart before meals versus standard therapy with sliding scale insulin in non-critical ill hospitalized patients with type 2 diabetes.
The design of the trial is an open, randomized controlled trial with two parallel arms (treatment arm and control arm). Randomization is 1:1.
Studietype
Registrering (Forventet)
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
- Navn: Merete B Christensen, MD
- Telefonnummer: 23811264
- E-post: merete.bechmann.christensen.01@regionh.dk
Studer Kontakt Backup
- Navn: Kirsten Norgaard, DMSC
- E-post: kirsten.noergaard@regionh.dk
Studiesteder
-
-
-
Hvidovre, Danmark, 2650
- Rekruttering
- Hvidovre University Hospital
-
Ta kontakt med:
- Merete B. Christensen, MD
- Telefonnummer: +4538623389
- E-post: merete.bechmann.christensen.01@regionh.dk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- History of type 2 diabetes for at least 6 months
- Age 18 - 90 years
- Pre-meal plasma glucose in the range 10 - 22,2 mmol/L prior to inclusion
- Expected hospital stay longer than 4 days
Exclusion Criteria:
- Hyperglycemia without known history of type 2 diabetes
- Type 1 diabetes mellitus
- Severely impaired renal function (eGFR ≤ 30 mL/min/1,73 m2)
- Severe hepatic disease
- Cardiac disease defined as: Decompensated heart failure (NYHA class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months
- Pregnant or lactating women or fertile female patients not using chemical, hormonal or mechanical contraceptives or not in menopause (i.e. must not have had regular menstrual bleeding for at least one year)
- Planned treatment during hospital stay with intravenous glucose/ insulin for ≥ 12 hours
- Treatment at admission or planned treatment during hospital stay with parenteral nutrition or enteral nutrition (i.e. gastroenteric tube feeding)
- Treatment at admission or planned treatment during hospital stay with high dose glucocorticoids (>40 mg)
- History or presence of malignancy (except basal skin cancer) unless a disease-free period exceeding five years
- Presence of alcohol or drug abuse
- Inability to understand the written information or incapability to provide informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Intervention
Basal-bolus insulin regime with Insulin Degludec and insulin aspart
|
Basal-bolus insulin regime
|
Ingen inngripen: Standard
Standard treatment according to hospital guidelines with sliding scale insulin
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Difference in mean daily plasma glucose between the two groups
Tidsramme: Duration of hospital stay, an expected average of 8 days
|
Difference in mean daily plasma glucose between the two groups, calculated by using the four daily pre-meal and bedside PG values per patient.
|
Duration of hospital stay, an expected average of 8 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Mean number and rates of hypoglycemic events (PG ≤ 3.9 mmol/L)
Tidsramme: Duration of hospital stay, an expected average of 8 days
|
Based on bedside PG measures and on CGM data
|
Duration of hospital stay, an expected average of 8 days
|
Time spent in glycemic range
Tidsramme: Duration of hospital stay, an expected average of 8 days
|
Based on bedside PG measures and on CGM data
|
Duration of hospital stay, an expected average of 8 days
|
Time spent in hyperglycemic range
Tidsramme: Duration of hospital stay, an expected average of 8 days
|
Based on bedside PG measures and on CGM data
|
Duration of hospital stay, an expected average of 8 days
|
Length of hospital stay
Tidsramme: Duration of hospital stay, an expected average of 8 days
|
Mean duration of hospital stay
|
Duration of hospital stay, an expected average of 8 days
|
Difference in insulin dose between groups
Tidsramme: Duration of hospital stay, an expected average of 8 days
|
Calculated as mean insulin dose during admission
|
Duration of hospital stay, an expected average of 8 days
|
Number of hospital acquired infections during admission
Tidsramme: Duration of hospital stay, an expected average of 8 days
|
Data from hospital record
|
Duration of hospital stay, an expected average of 8 days
|
Number of post-discharge infections or re-admissions 1 month after discharge
Tidsramme: 1 month
|
Data collected on follow-up 1 month after discharge
|
1 month
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Kirsten B Norgaard, DMSC, Hvidovre University Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- U1111-1177-2744
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 2 diabetes mellitus
-
University Hospital Inselspital, BerneFullført
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Fullført
-
US Department of Veterans AffairsAmerican Diabetes AssociationFullførtType 2 diabetes mellitusForente stater
-
Dexa Medica GroupFullførtType-2 diabetes mellitusIndonesia
-
AstraZenecaRekruttering
-
Daewoong Pharmaceutical Co. LTD.Har ikke rekruttert ennåT2DM (type 2 diabetes mellitus)
-
Zhongda HospitalRekrutteringType 2 diabetes mellitus (T2DM)Kina
-
Newsoara Biopharma Co., Ltd.RekrutteringT2DM (type 2 diabetes mellitus)Kina
-
Shanghai Golden Leaf MedTec Co. LtdAktiv, ikke rekrutterendeType 2 diabetes mellitus (T2DM)Kina
-
SanofiFullført
Kliniske studier på Insulin Degludec 100 UNT/ML [Tresiba]
-
Diasome PharmaceuticalsIntegriumFullførtDiabetes mellitus, type 1Forente stater
-
University Hospital TuebingenAvsluttetDiabetes mellitus, type 2Tyskland
-
Novo Nordisk A/SFullført
-
SanofiAvsluttetType 2 diabetes mellitus | Nedsatt nyrefunksjonForente stater, Tsjekkia, Ungarn, Polen, Serbia
-
SanofiFullførtType 1 diabetes mellitusTyrkia, Nederland, Brasil, Forente stater, Tyskland, Ungarn, Storbritannia
-
SanofiFullførtDiabetes mellitus, type 2Israel, Tsjekkia, Hellas, Italia, Forente stater, Bulgaria, Kroatia, Danmark, Frankrike, Ungarn, Romania, Serbia, Slovakia, Sverige, Sveits, Storbritannia
-
Changhua Christian HospitalRekrutteringDiabetisk ketoacidose | Hyperglykemisk krise ved diabetes mellitus | Hyperglykemisk hyperosmolart nonketotisk syndromTaiwan
-
Novo Nordisk A/SFullførtDiabetes mellitus, type 2Forente stater, Polen, Puerto Rico, Canada, Ungarn, Tyskland, Tyrkia, Hellas
-
Diasome PharmaceuticalsIntegriumFullførtType 1 diabetes mellitusForente stater